Clinical Trials

Zealand Pharma announced that the first patient has been dosed in a Phase 2 clinical trial of the long-acting GLP-1/glucagon dual agonist BI 456906, which Zealand has licensed to Boehringer Ingelheim. As part of the license agreement, Zealand will...

Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials. Under...

PTC Therapeutics, Inc. announced that the U.S. FDA has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19. PTC299 is an oral investigational drug with a...

The study will be the first time Imperial’s vaccine has been trialled in humans and will assess whether it is well-tolerated and produces an effective immune response against Covid-19. The trial will recruit 300 healthy participants who will then receive...

Eli Lilly will assess its JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study. Indianapolis-based Eli Lilly said the latest study will complement an ongoing study of the rheumatoid arthritis drug being conducted in...

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that it has dosed the first patient in a Phase 2 study evaluating its lead therapeutic candidate, ATYR1923,...

TrialSpark, a tech-enabled drug development company committed to improving the speed, quality, and innovation of clinical trials, announced the launch of Project Covalence, a turnkey trial platform that enables investigators and sponsors to rapidly launch clinical trials for COVID-19....